Bibliography
- Global atlas on cardiovascular disease prevention and control. Available from: http://www.who.int/cardiovascular_diseases/en/ [Last accessed 26 April 2012]
- Cardiovascular Pharmaceutical Market Trends, 2007 to 2010. Available from: http://www.urchpublishing.com/publications/therapeutic/cardiovascular_pharmaceutical_market_trends_2007_2010.html [Last accessed 26 April 2012]
- Drugs, money, and glory: Is cancer beating cardiovascular disease?. Available from: http://www.theheart.org/article/1261569/print.do [Last accessed 26 April 2012]
- Programs–GRNCM1. Available from: http://cell-therapies.geron.com/grncm1 [Last accessed 9 April 2012]
- Geron Announces Preclinical Study Data of GRNCM1. Available from: http://ir.geron.com/phoenix.zhtml?c=67323&p=irol-newsArticle&ID=1635737&highlight= [Last accessed 9 April 2012]
- Geron to Focus on its Novel Cancer Programs. Available from: http://ir.geron.com/phoenix.zhtml?c=67323&p=irol-newsArticle&ID=1635764&highlight [Last accessed 9 April 2012]
- LATE BREAKING ABSTRACTS 70th Scientific Sessions. Available from: http://professional.diabetes.org/admin/UserFiles/file/SciSessions/2010%20Abstracts/2010%20ADA%20LB%20Abstracts.pdf [Last accessed 21 May 2012]
- Annual report pursuant to section 13 and 15(d). Available from: http://www.gilead.com/AR2011/GileadSciences_10K_20120223.pdf [Last accessed 9 April 2012]
- Fatholahi M, Xiang Y, Wu Y, A novel partial agonist of the A(1)-adenosine receptor and evidence of receptor homogeneity in adipocytes. J Pharmacol Exp Ther 2006;317:676-84
- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549. Available from: http://www.sec.gov/Archives/edgar/data/874015/000110465911011094/a10-24306_110k.htm [Last accessed 21 May 2012]
- NicOx receives €5 million milestone payment from Merck & Co. for antihypertensive collaboration. Available from: http://www.nicox.com/files/pdf/PR2007011800EN.pdf [Last accessed 11 April 2012]
- NicOx 2010 Financial Results. Available from: http://www.nicox.com/files/pdf/PR2011022400EN.pdf [Last accessed 11 April 2012]
- NicOx presents preclinical results at AHA from antihypertensive collaboration with Merck & Co., Inc. Available from: http://www.nicox.com/files/pdf/PR2006111400EN.pdf [Last accessed 12 April 2012]
- NicOx announces initiation of first phase 1 study of investigational nitric oxide-donating agent in hypertensive patients by Merck & Co., Inc. Available from: http://www.nicox.com/files/pdf/PR2008051300EN.pdf [Last accessed 11 April 2012]
- NicOx and Merck to broaden scope of license Agreement. Available from: http://www.nicox.com/files/pdf/PR2010091500EN.pdf [Last accessed 11 April 2012]
- Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS). Available from: http://clinicaltrials.gov/ct2/show/NCT00748501?term=sb-509&rank=1 [Last accessed 21 May 2012]
- Sangamo BioSciences Announces Phase 2b Trial of SB-509 in Diabetic Neuropathy Did Not Meet Key Study Endpoints. Available from: http://investor.sangamo.com/releasedetail.cfm?ReleaseID=610157 [Last accessed 21 May 2012]
- Furiex Announces Results for Phase II Trial of PPD-10558. Available from: http://investor.furiex.com/releasedetail.cfm?ReleaseID=631793 [Last accessed 22 May 2012]
- Development activities. Available from: http://www.takeda.com/pdf/usr/default/11_40972_2.pdf [Last accessed 24 May 2012]
- Flovagatran will not be pursued. Available from: http://www.paion.de/images/stories/investoren/finanznachrichten/2010/en/paionp101206en.pdf [Last accessed 24 May 2012]
- ANNUAL REPORT 2010. Available from: http://www.asm2011.bayer.com/en/bayer-annual-report-2010.pdfx [Last accessed 24 May 2012]
- Investor Handout Meet Management. Available from: http://www.investor.bayer.com/user_upload/3763/Meet_Management_2011_Investor_Handout_Final.pdf [Last accessed 24 May 2012]
- UNITED STATES SECURITIES AND EXCHANGE COMMISSION. Available from: http://en.sanofi.com/Images/29804_20F_2011.pdf [Last accessed 24 May 2012]
- Product Fact Sheet. Available from: http://www.aryx.com/pdf/factsheet_budiodarone.pdf [Last accessed 29 June 2012]
- Budiodarone (ATI-2042) - Atrial Fibrillation. Available from: http://www.aryx.com/wt/page/ati2042 [Last accessed 24 May 2012]
- Histalean achieves mixed results at Ph II. Available from: http://www.thepharmaletter.com/file/20010/histalean-achieves-mixed-results-at-ph-ii.html [Last accessed 22 May 2012]
- Bio-Light closes obesity treatment co OBEcure [Globes, Tel Aviv, Israel]. Available from: http://www.therapeuticsdaily.com/news/article.cfm?contentValue=1979964&contentType=sentryarticle&channelID=28 [Last accessed 22 May 2012]
- A Dose-Ranging Study of the Safety and Efficacy of ADX415 in the Treatment of Essential Hypertension. Available from: http://clinicaltrials.gov/ct2/show/NCT00779181 [Last accessed 21 May 2012]
- Financial Results for the First Quarter of Fiscal Year 2011(Consolidated). Available from: http://www.shionogi.co.jp/ir_en/materials/detail/con11_08.pdf [Last accessed 9 May 2012]
- Product Fact Sheet. Available from: http://www.aryx.com/pdf/factsheet_tecarfarin.pdf [Last accessed 29 June 2012]
- Aryx Therapeutics' anticoagulant not superior to warfarin in Phase II/III trial; shares fall. Available from: http://www.verusmed.com/articles/view/60958/ [Last accessed 21 May 2012]
- Tecarfarin (ATI-5923) – Anticoagulation. Available from: http://www.aryx.com/wt/page/ati5923 [Last accessed 21 May 2012]
- Astellas Pharma, Inc. Discontinues Development of Darexaban (YM150), an Oral Direct Factor Xa Inhibitor. Available from: http://www.astellas.com/en/corporate/news/detail/astellas-pharma-inc-discontinu.html [Last accessed 24 May 2012]
- RISK ASSESSMENT and RISK MITIGATION REVIEW(S). Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021560s000riskr.pdf [Last accessed 9 April 2012]
- An Observational Safety Evaluation of Patients Treated With the NEVO™ Sirolimus-eluting Coronary Stent. Available from: http://clinicaltrials.gov/ct2/show/NCT01202058?term=EC09-01&rank=1 [Last accessed 9 April 2012]
- Cordis Announces Discontinuation Of Nevo™ Sirolimus-Eluting Coronary Stent. Available from: http://www.jnj.com/connect/news/all/cordis-announces-discontinuation-of-nevo-sirolimus-eluting-coronary-stent [Last accessed 9 April 2012]
- Sirolimus. Available from: http://www.nlm.nih.gov/medlineplus/druginfo/meds/a602026.html#other-uses [Last accessed 9 April 2012]
- Juvista in Scar Revision Surgery of Disfiguring Scars (Revise). Available from: http://clinicaltrials.gov/ct2/show/NCT00742443?term=NCT00742443&rank=1 [Last accessed 24 May 2012]
- Juvista EU Phase 3 trial results. Available from: http://www.renovo.com/zh-hans/news/juvista-eu-phase-3-trial-results [Last accessed 24 May 2012]
- RENOVO ANNOUNCES MAJOR RESTRUCTURING. Available from: http://www.renovo.com/hi/news/renovo-announces-major-restructuring [Last accessed 24 May 2012]
- Amsterdam Molecular Therapeutics Provides Operations Update and Strategic Review of Pipeline. Available from: http://www.amtbiopharma.com/news/135/182/Amsterdam-Molecular-Therapeutics-Provides-Operations-Update-and-Strategic-Review-of-Pipeline.html [Last accessed 21 May 2012]
- Zhao HP, Zhang XS, Xiang BR. Discontinued drugs in 2010: cardiovascular drugs. Expert Opin Investig Drugs 2011;20:1311-25